Santhera Pharmaceuticals is approaching cash flow break-even in Q3 2026, driven by strong uptake of its drug AGAMREE for Duchenne muscular dystrophy in Europe. AGAMREE, a corticosteroid with fewer side effects, has captured significant market share in Germany and Austria, with UK adoption following. Planned launches in Spain and Italy and a hybrid commercial model with licensing partnerships globally support growth. The company aims for CHF80-90 million revenue in 2026 and €150 million by 2028, backed by a $40 million upfront payment from a licensing deal in Asia-Pacific.
An analyst from Scotiabank raised the price target for Public Storage (NYSE: PSA) to $346, suggesting a potential 5.75% upside from the current price of $327.18. Institutional investors like Capital Financial Group and Harvest Fund Management have in...
Corporacion America Airports reported Q2 2026 revenue of $534 million, surpassing analyst estimates of $497.52 million, showing strong sales performance. However, earnings per share (EPS) came in at $0.32, below the expected $0.51, indicating lower p...
Analysts have raised their price targets for Cheniere Energy, signaling confidence in the company's future growth. Argus increased its target to $330, suggesting a 20.33% upside from the current price of around $274. TD Cowen also raised its target t...
KeyBanc and DA Davidson upgraded Duolingo's stock rating, citing positive sentiment and raising price targets to $137.11 and $160 respectively. This upgrade lifted Duolingo shares by 4.3% in pre-market trading to $135.71. Despite this optimism, most ...
ReNew Energy Global exceeded analyst expectations in Q1 FY2027 by reporting EPS of $0.17 versus $0.12 estimated and revenue of $506.4 million, surpassing the $459.86 million forecast. The company expanded its renewable energy portfolio to about 20.5 ...
